Moleculin Biotech MBRX 深 沪
等待开盘 10-30 09:30:00 美东时间
0.4796
-0.003
-0.68%
华盛通- 最 高0.50
- 今 开0.4822
- 成交量 155.17万股
- 最 低 0.4654
- 昨 收 0.4829
- 总市值 2373.95万
- 52周最高 3.6499
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.25
- 委 比 -95.90%
- 总股本 4949.86万
- 历史最高 862.20
- 量 比 0.69
- 振 幅 7.17%
- 历史最低 0.25
- 每 手 1
- 风险率 0.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Moleculin Biotech Secures Australian Patent for Annamycin
Moleculin Biotech ( ($MBRX) ) has shared an announcement. On October 29, 2025, ...
10-29 20:59
Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin
Houston, Oct. 29, 2025 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc. announced that the Australian Patent Office granted Patent No. 2024203598 titled "PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE," which covers preliposomal Annamycin lyophilizates with improved stability and high purity. The patent extends until June 2040 and strengthens the company's global IP portfolio. Walter Klemp, CEO, highlighted the importance of this patent in building...
10-29 12:35
Moleculin Biotech Enters Collaboration With Atlantic Health On An Investigator-Initiated Phase 1B/2 Study To Evaluate Its Drug Candidate Annamycin As A Third-Line Treatment For Advanced Pancreatic Cancer
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced
10-23 20:05
Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer
Moleculin Biotech is collaborating with Atlantic Health on a Phase 1B/2 clinical trial evaluating Annamycin as a third-line treatment for advanced pancreatic cancer. Preclinical studies suggest Annamycin targets critical factors in pancreatic cancer, with potential advantages due to its high affinity for the pancreas and lack of cardiotoxicity. Walter Klemp, CEO of Moleculin, expressed excitement about the study, highlighting Annamycin's potentia...
10-23 12:00
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, Oct. 21, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – Conventional small molecule approaches hav...
10-21 21:20
Moleculin Biotech Stockholders Approve Share Issuance
Moleculin Biotech ( ($MBRX) ) has shared an update. On October 16, 2025, Molecu...
10-16 23:48
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
Mainz Biomed's feasibility study for a non-invasive blood-based pancreatic cancer screening test achieved 100% sensitivity and 95% specificity, distinguishing pancreatic cancer patients from healthy controls, including those with precancerous lesions. The algorithm, using 18 licensed biomarkers, showed consistency with previous results, highlighting potential for early detection and monitoring. The company plans larger clinical studies to validat...
10-08 13:00
Moleculin Biotech Secures Canadian Patent Titled "PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE"
Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance f
09-25 20:40
Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin
<p>Moleculin Biotech 宣布，加拿大知识产权局已批准其关于生产高稳定性和高纯度的前脂质体Annamycin冻干粉的方法的专利申请。该专利预计将于未来几个月内正式授权，基本专利期限将持续至2040年。Annamycin 是一种新型药物候选，旨在成为首个获批的非心脏毒性蒽环类药物，目前正针对急性髓性白血病（AML）和软组织肉瘤肺转移（STS肺转移）进行开发。此外，该药物还显示出在治疗多种癌症类型方面的潜力。Moleculin公司正在加强其在全球范围内的知识产权组合，此前已在美欧获得相关专利授权。公司首席执行官Walter Klemp表示，将继续致力于通过强化知识产权保护，推动Annamycin成为治疗难治性肿瘤的变革性候选药物。</p>
09-25 12:35
